Revolution Medicines is trading at $190.08, up 4.35%, at 9:58 a.m. EST on October 20, 2026, amid broader biotech-sector strength.
- XBI was up 2.09%, with sector sentiment supported by Merck KGaA’s acquisition of Silence Therapeutics and anticipation of cancer data.
- Reuters reported the approximately $1.3 billion deal on October 19. No clear new Revolution Medicines-specific catalyst emerged in the available search, pointing to sector-level support rather than a confirmed company-specific trigger.